+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Germany Cancer Biomarker Market 2019-2025

  • ID: 5116750
  • Report
  • February 2020
  • Region: Germany
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Becton, Dickson and Co.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Merck and Co., Inc.
Germany Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker, and Protein Biomarker), by Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Other), by Applications (Drug Discovery and Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period 2019-2025.

Germany cancer biomarker market is anticipated to grow at a CAGR of 11.8% during the forecast period. Germany has well developed healthcare system and favorable government policies which are driving the global cancer biomarker market in the region. Adoption of specialized procedures to treat cancer, extensive R&D in the cancer treatments and presence of globally renowned major hospitals, research centers and clinics are contributing to the growth of the market. The healthcare expenditure of Germany in 2013 was 11.6% as compared to the OECD average of 8.9%. The healthcare of Germany is driven by the specific mechanisms that determine the utilization of health care in the elderly. In Germany health insurance is mandatory for the entire population Regardless of the type of health insurance, all beneficiaries have has accessed by outpatient physician and non-physician services, hospital care, rehabilitation, dental care, prescription drugs, medical supplies and long-term nursing care.

Germany has well-developed healthcare infrastructure. A number of organizations has been established in the country regarding research activities, which significantly contributes to the Germany cancer biomarker market. German Cancer Aid was established in 1974, in order to promote research, improve care for cancer patients and increase cancer awareness through information, education and public campaigns. Krebsallianz GmbH is a medical relief program focused on cancer and is funding childhood cancer research in Germany. German Children's Cancer Foundation is established to provide support, social fund, aftercare, pirate forest camp, cancer information and supporting research in 1995.

Apart from cancer organization, a number of cancers centers has been established. Cancer centers can be defined as hospitals and research institutes cater to a designated region. Some of the major cancer center are Centre for Integrated Oncology (CIO), Charité Comprehensive Cancer Centre, Comprehensive Cancer Centre Erlangen EMN, National Centre for Tumor Diseases (NCT) Heidelberg, Tumor Centre Freiburg, University Centre for Tumor Diseases Frankfurt (UCT), University Cancer Centre Hamburg, West German Tumor Centre. Thus, this is expected to influence the growth of the Germany cancer biomarker market during the forecast period.

Research Methodology:

The market study of the Germany cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Germany Cancer Biomarker Market Research and Analysis by Biomarker Type
2. Germany Cancer Biomarker Market Research and Analysis by Cancer Type
3. Germany Cancer Biomarker Market Research and Analysis by Application

4. Germany Cancer Biomarker Market Research and Analysis by Profiling Technology

The Report Covers:
  • Comprehensive Research Methodology of the Germany Cancer biomarker market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Germany Cancer biomarker market.
  • Insights about market determinants which are stimulating the Germany Cancer biomarker market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Becton, Dickson and Co.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Merck and Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • QIAGEN GmbH
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown